• MediWound highlighted EscharEx as its lead growth program, targeting a USD 2.5 billion-plus U.S. chronic-wound market; venous leg ulcer study remains in Phase 3.
• EscharEx expansion plans include a diabetic foot ulcer Phase 2 trial in H2 2026; a pressure-ulcer study is also planned.
• NexoBrid burn therapy delivered USD 17 million revenue in 2025; approved in the U.S., Europe and Japan for adult and pediatric patients.
• Cash totaled USD 45 million as of March 31, 2026, with no debt; up to an additional USD 30 million tied to Series A warrants expiring in November 2026.
• A new cGMP sterile manufacturing facility is expected to receive regulatory approvals in 2026; capacity expansion is projected to lift gross margin to 65%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.